Overview
Dr. Becker is currently a Professor of Pediatrics and the Vice Dean for Faculty at Duke University School of Medicine. Prior to arriving at Duke in 2019, she spent 13 years at Children’s Mercy, Kansas City where she completed additional fellowship training in pediatric clinical pharmacology and served as Division Director of Rheumatology and Associate Chair for the Department of Pediatrics. At Duke, Dr. Becker served as the Vice Chair for Faculty in Pediatrics, until she assumed the role of Vice Dean for Faculty in July, 2022.
Dr. Becker’s translational research interest is to identify factors that enhance response and minimize toxicity to drugs used for the treatment of diseases in children, focusing on an individualized therapeutic strategy. Her work focuses on methotrexate and its effect upon the folate pathway, utilizing cellular biomarkers and genetic differences to predict drug efficacy in patients with JIA. Her research has been funded by the Kansas City Area Life Sciences Institute, the PhRMA Foundation, the Rheumatology Research Foundation, and the National Institutes of Health. She has also served as a faculty leader at the Duke Clinical Research Institute where her work expanded to developing and supporting novel networks to carry out research and clinical trials, focusing on children with rare rheumatic and genetic conditions including the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.
In her new role as Vice Dean, she has focused on fortifying and reimagining the Office for Faculty and the multiple programs and offices that support faculty in the School of Medicine. New efforts in this role will focus on identifying opportunities to create standardized and transparent processes within the office, prioritizing leadership development for current leaders in the School of Medicine, and developing a training and mentorship program in Restorative Justice to strengthen community and support a healthy and productive work climate. In addition to her administrative work at Duke, Dr. Becker has held multiple leadership roles in national committees and organizations in her field.
Current Appointments & Affiliations
Recent Publications
Plasma metabolic profiling identifies elevated hippurate as a potential biomarker of methotrexate non-response in juvenile idiopathic arthritis.
Journal Article Biomed Pharmacother · December 2025 BACKGROUND / PURPOSE: Methotrexate (MTX) continues to be the first-line disease-modifying antirheumatic drug (DMARD) in the treatment of juvenile idiopathic arthritis (JIA). However, response to MTX is often delayed and variable, requiring the initiation o ... Full text Link to item CiteLong-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.
Journal Article Pediatr Rheumatol Online J · October 21, 2025 BACKGROUND: Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation. The introduction of biologics has improved the treatment options for SJI ... Full text Link to item CiteThree-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study.
Journal Article Arthritis Rheumatol · October 2025 OBJECTIVE: To assess the impact of differences in the timing of initial biologic disease-modifying antirheumatic drug (bDMARD) therapy using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Start Time Optimization of biologics in Polyarti ... Full text Link to item CiteRecent Grants
Clinical Pharmacokinetics and Safety Trials in Down Syndrome
Clinical TrialPrincipal Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2019 - 2026Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2021 - 2026Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis
ResearchAdvisor · Awarded by National Institutes of Health · 2020 - 2025View All Grants